Get started

Pharmaceuticals

Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment. Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position. Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case. Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above. Here on my macroeconomic and current research shortlist watchlists: www.tradingview.com www.tradingview.com Thanks for reading, have a good one
SIX:RO
by sihen999
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!). After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines. The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
NASDAQ:GILDLong
by EmptyEternity
1
#PHA/USDT#PHA The price is moving in a bearish channel pattern on the 4-hour frame, and it adheres to it well, and it is expected to break to the upside The price rebounded well from the lower border of the channel at the green support level 0.1650, which is a strong level. We have a tendency to stabilize above the Moving Average 100 We have oversold resistance on the RSI indicator to support the rise, with a downtrend about to break higher Entry price is 0.1900 The first target is 0.2330 The second target is 0.2600 The third goal is 0.2884
Long
by CryptoAnalystSignal
UPDATE: Target Reached Aspen R206.03 - Next target higherSymmetrical Triangle was a a text book trade. The previous trend was up. Price broke above the apex 3/4s in and the momentum continued up. We had further indicators of confirmation for upside to come. Price>20 Price>200 Target 1 R206.03 So what now? Well we can expect somewhat a consolidation, and a potential Cup and Handle to form. Then we have the next target above R221. It might be messy to buy now, but in good time it should present a great opportunity. I'll let you know.
JSE:APNLong
by Timonrosso
Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand name for ALS. In this disease, nerve cells break down, reducing muscle function. The Food and Drug Administration approved Relyvrio based on a single study in September 2022. But Amylyx ( NASDAQ:AMLX ) continued on with a Phase 3 study. Now, Amylyx ( NASDAQ:AMLX ) is deciding whether to voluntarily pull the drug from the market in the U.S. and Canada. In Canada, it sells under the brand name Albrioza. Technical Analysis On today's stock market, Amylyx ( NASDAQ:AMLX ) stock plummeted 82.9% to 3.36. Shares undercut their 50-day and 200-day moving averages, MarketSurge.com shows. That put shares at a record low. Way Forward For Amylyx Stock? It's important to note that Relyvrio failed to make a difference across multiple measures, including the key goal of the study: improvement on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. The company tested Relyvrio over 48 weeks. Secondary measures of the study also flopped. Amylyx ( NASDAQ:AMLX ) says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.
NASDAQ:AMLXShort
by DEXWireNews
Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O). Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax ( NASDAQ:NVAX ) remains undeterred in its pursuit of market dominance. Chief Executive John Jacobs acknowledges the company's disappointing performance during the recent vaccination campaign, attributing it to delayed market entry and logistical challenges. However, Jacobs remains resolute in his commitment to enhancing Novavax's competitive positioning and expanding its footprint in the burgeoning vaccine landscape. A key focal point of Novavax's ( NASDAQ:NVAX ) strategy is the pursuit of pre-filled syringes, a format favored by consumers and healthcare providers alike for its convenience and ease of use. Jacobs emphasizes the importance of targeted sales efforts and broad retail availability to drive uptake and accelerate market penetration. Despite near-term revenue challenges, Novavax ( NASDAQ:NVAX ) remains optimistic about its long-term prospects, projecting revenue for 2024 in the range of $800 million to $1 billion. The company's commitment to cost containment and operational efficiency underscores its determination to navigate uncertainties and drive sustainable growth in the years ahead. Novavax's ( NASDAQ:NVAX ) journey has been marked by highs and lows, from soaring market valuations to regulatory hurdles and manufacturing setbacks. However, the company's resilience and adaptability position it well to overcome obstacles and emerge as a formidable player in the global fight against COVID-19. While challenges persist, including lingering doubts about the company's financial viability, Novavax remains focused on execution and delivering value to stakeholders. Jacobs's emphasis on operational improvements and leaner processes reflects a renewed commitment to efficiency and effectiveness in the commercial market. As Novavax ( NASDAQ:NVAX ) embarks on this pivotal phase of its journey, investors and industry observers await eagerly to witness the company's ability to translate strategy into tangible results. With determination, perseverance, and a renewed sense of purpose, Novavax ( NASDAQ:NVAX ) seeks to redefine its narrative and carve out a prominent place in the annals of vaccine innovation.
NASDAQ:NVAX
by DEXWireNews
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
ALKEM Near All time high ALKEM is Near all time high Alkem is in a Rising channel and Resistance is working from last 8 years Stock is facing resistance around 5500 for the further upside Stock need to cross 5500 If stock tanks then we might see level of 3100-3200 3100-3200 is strongest support and one should not miss opportunity to BUY around these levels. Thank You !! Disclaimer : We are not SEBI registered analyst. Do your own research before taking any investment decision.
NSE:ALKEMShort
by FiveCircles
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Exscientia's Bold Leap Forward in AI-Driven PharmaIntroduction: A Turbulent Turnaround Exscientia plc (NASDAQ: EXAI), a pioneering force in AI-driven pharmaceuticals, recently faced a storm that tested its core. Amidst leadership controversies, the company has not just weathered the storm but is poised for a transformative leap, signaling a potent mix of resilience and innovation. Recent Financial Performance and Market Dynamics As of the latest update, Exscientia's shares experienced a modest uptick, closing at $6.92, marking a 2.67% increase. This movement reflects a dynamic response to both internal shifts and the broader market's reception. Notably, the company's market cap stands at approximately $864.585 million, with a trading volume that underscores robust investor interest. The EPS (TTM) is currently at -1.47, indicating the investment-heavy phase typical of pioneering tech-driven entities. The anticipation builds as the earnings date approaches, scheduled between March 18, 2024, and March 22, 2024, promising insights into the company's trajectory. A Leadership Shakeup with a Silver Lining Exscientia's recent headlines have been dominated by the dismissal of its CEO, Andrew Hopkins, following an investigation into "inappropriate" relationships with employees. This leadership crisis, however, has not dampened the company's spirit or its commitment to groundbreaking work in AI and pharmaceuticals. Instead, it has catalyzed a reflective reevaluation of its corporate culture and governance, setting the stage for a renewed focus on innovation and ethical leadership. Growth Drivers and Innovation at the Helm Despite the challenges, Exscientia remains at the forefront of integrating AI with pharmaceutical development. The initiation of EXCYTE-2, an observational clinical study in acute myeloid leukemia (AML), exemplifies its commitment to leveraging deep learning and single-cell precision medicine platforms. This study aims to investigate the relationship between ex vivo drug response and actual patient clinical responses, heralding a new era in personalized medicine. Technical and Market Outlook: A Resilient Trajectory The stock's technical indicators reveal a bullish pattern, with a day's range showing a high of $7.20, suggesting volatility and investor interest. The broader outlook remains positive, with analysts eyeing a potential upside, reflecting confidence in Exscientia's technological edge and market position. Conclusion: Navigating the Future with Precision and Purpose Exscientia's journey through recent turmoil to a place of potential and promise is a testament to the resilience and transformative power of innovation. As it embarks on a new chapter, free from the shadows of the past and driven by a commitment to revolutionizing healthcare through AI, Exscientia stands as a beacon of progress in the ever-evolving pharmaceutical landscape. --------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
ELong
by olimchik
1
TNXP: Tonix Pharmaceuticals, TIME FOR PROFITS?!? ;)What's up my financial amigos and amigas! Hope all is well. Haven't posted in awhile but thought I'd share this: TNXP. Pharmaceutical company with decent history and negative earnings but continued improvement and growth. Working on approval from FDA after successful phase 3 trial of Fibromyalgia drug (among other projects). Obviously, this is a more risky stock/company (and of course, I do enjoy a good gamble). This could certainly plummet more and/or result in being stuck in longer term position than desired. However, based on prior patterns of "mooning," coupled with my charting projections and current positive "news," I think it's time for at least a 100% pump. We'll see...not financial advise and do your own research (and send me 10% of profits...jk, sort of). Projection: >10 trading days for 50-100+ percent Good luck trading
NASDAQ:TNXP
by TheLuckyNoob
Eli Lilly Breaks New Ground With Weight Loss Drug Offering Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter revenue of $9.35 billion, up 28% from the same period a year ago. A massive result that is reflected in the chart and pre-market surge in price per a share from €706 - €740 👀 Eli develop and manufacture a series of medications with their top drugs being for diabetes and cancer. The diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly in 2022 accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. Meanwhile for 2023, Trulicity, reported $1.67 billion in revenue. That’s down 14% from the same period a year go however remains a large revenue generator. Mounjaro booked $2.21 billion in sales for the fourth quarter and remains one of the companies core diabetes products. The Q4 2023 results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early Nov 2023. Zepbound resulted in $175.8 million in sales for Q4. Analysts are expecting a minimum of $1 billion in sales for the 2024 period and some are claiming that Zepbound could become the biggest drug of all time. Do you feel that AI style narrative euphoria building here? Now more importantly, Lets check out this chart The Chart The chart here really caught my attention, its one of thee strongest long term charts I have come across and it keeps making higher double bottoms off higher moving averages. The OBV is increasing still and the support line might be a good line to watch got an entry bounce or a break down (exit) - a trigger level. PUKA
NYSE:LLYLong
by PukaCharts
Solara - The Sun is Rising Behind the PyramidSolara Active Pharma: After the CEO of Solara resigned 1.5 years ago, the Company shares faced a major crash - retracing near 100% on Fib scale. A large Pyramid like structure was formed eventually Over the past few months - the price has started to strengthen the base taking support near the 290-300 zone which is one the Strongest support for the script A Bullish Reversal sign is seen when a Right Angled Triangle pattern was formed and successfully breaking out of the Pattern along with the next immediate resistance at 410. I can also be seen as a Double Bottom pattern - long long way to go Its changing direction from being a Sunset company to a Sunrise company. With the Breakout of Pharma sector, many Pharma companies are having their dream run and SOLARA is riding the journey along with its peers. The Sun is Rising behind the Tall Pyramid. Wait for Large Targets ahead - 550, 830, 1200 Disclaimer: Stocks-n-Trends is NOT a SEBI registered company. We do not provide Buy / Sell recommendations - rather we provide detailed analysis of how to review a chart, explain multi--timeframe views purely for Educational Purposes. We strongly suggest our followers to "Learn to Ride the Tide" and consult your Financial Advisors before taking any positions. If you like our detailed analysis, please do rate us with your Likes, Boost and share your comments -Team Stocks-n-Trends
NSE:SOLARALong
by Stocks-n-Trends
Cup and Handle kind of Breakout on cards for Pharma Index. Technically Pharma index is on the verge of giving a cup and handle like breakout in addition to news of new COVID variant making waves. The Pharma index also looking very buoyant. If this particular index can give a closing above 16515 there can be an upsurge 16734 or even 17177 levels taking the index constituents higher along with it. Major companies in pharma index are Abbott, Cipla, Glaxo, Sanofi, Pfizer, Dr Reddy's, Lupin, Torrent Pharam, Ipca Labs, Sun Pharma, Aurobind Pharma, Natco Pharma, Granules India, Gland Pharma, Alkem, Biocon, Glenmark, Zydus Lifescience, Divi's lab, Laurus lab. Some companies good companies of Mid and Small cap pharma can also yield positive momentum. Post identification of a strong index what you can do is try to look at the charts of each constituent of the index individually and select the stocks with best EPS, PE ratio, Good Cash flow from operations, Revenue and Net Profit growing year on year and quarter on quarter. Remember that now all the stocks in an index will move equally some will move faster, some will move at the same pace, some will move slowly and some will not move at all or move negatively. You have to be smart in selection of your stocks from the particular index and you will surely be able to beat the market and Ace the art of investing. There are many Pharma related Mutual funds that can also be looked at. Disclaimer: Investment in stocks and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks given in the above article and chart of IT Index is only for analysis. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
NSE:CNXPHARMALong
by Happy_Candles_Investment
Long Rubles Big PharmaAs you can see on the presented chart first goes Gilead Sciences, USA Pharmaceutical Giant which we see as the main sorce of income and R&D of USA Pharmaceuticals Industry. Main levels are 82.50, 79.00, 73.50, 69.00. Second is Pfizer, Europe Pharmaceutical giant, main levels are 54.50, 46.50, 28.50. Third is Merck, based, again, in Europe, main levels are 115.00, 80.50. Fourth is Bayer, a multinational Pharmaceutical Giant. Fifth is Life, biopharm company from Russia, main levels are, 9.00, 7.25, 4.70. Sixth is Diod, experimental and natural medicine company, main levels are 24.00, 15.50. We see a possibility of strong profits in coming quarters, due to the winter season and new R&D activities. Wee see these companies as a good opportunity for a risk oriented investor to hold for about twelve to twenty four months.
NASDAQ:GILDLong
by UnknownUnicorn462803
Ruble developing ground to restructure third world economiesOn the presented chart we have prepared, you can see correlations of Ruble currency with Telecoms, Steel producing, Concrete producing, Land transport and Medicine. As you can see Ruble is building a solid ground to become a back end for the developing world destroyed by conflicts and fist fights. ATR is going down and from the june it shows backward correlation with Ruble. This is good because this means Ruble can rise without volatility. Telecommunications prices are falling after this event. Steel producing showing strange pattern and can be a risk for the Ruble. Concrete producing and transportation developing a good foundation. Transportation industry is still and strong. And medicine industry showing weakness but we see rise in pharmaceuticals profits so we hope this will drag whole venture up.
by UnknownUnicorn462803
2
Weight loss - Stock GainEli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as diabetes, oncology, immunology, neuroscience, and other medical conditions. One notable aspect of their recent success is the introduction of a weight loss drug, tirzepatide. This drug is similar to other medications like Ozempic and Wegovy, which are also designed to help with weight loss. These medications are administered via weekly injections and work by affecting the patient's appetite by mimicking certain hormones in the gut. Wegovy, for instance, primarily mimics the hunger-regulating hormone called GLP-1, while tirzepatide goes a step further by mimicking both GLP-1 and another hormone called GIP. These hormonal effects can lead to decreased appetite, making it easier for individuals to manage their weight.
NYSE:LLYLong
by Helios_Capital_Investment
ELI LILLY Our gem on the verge of making a paradigm shift.Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May. This time the price reversed much quicker than technically expected and is attempting again to break the top (Higher Lows trend-line) of the Channel Up that started in 2020. If it closes above it, then we wil target the 3.0 Fibonacci Channel extension at $700. If it gets rejected and stays within the Channel Up, we will sell and target the recent Support at $520. Note that a break above this 3-year Channel Up may constitute a paradigm shift as the stock has never hit a new upper Fibonacci level that quickly (remember it broke above the 2.0 Fib just 5 months ago). This can transcend LLY into an even more aggressive bullish nature that we can't yet quantify. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1